Consistently with our in vitro data (Figure 5A, B), we observed that CRC patients with progressive disease (PD) have significantly lower PTPRO expression than patients with partial response (PR) and stable disease (SD) (p-value= 0.01869) (Figure 5C). This evidence concerns the gene PTPRO and colorectal carcinoma.